The full management from first-line to third-line treatments in patients with Her-2−negative advanced gastric cancer

Chunxiao Chang1, Yanqing Pei2, Jun Xu1, Wenyu Zhang3, Jianbo Zhang4 and Shengbin Shi1*

1Department of Gastrointestinal Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China, 2Department of Infection Management, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China, 3Department of Imaging, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China, 4Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China

Background: The aim of this study was to retrospectively evaluate the efficacy of full management from first-line to third-line treatments in patients with human epidermal growth factor receptor 2 (Her-2)−negative advanced gastric cancer (GC).

Methods: The efficacy and survival time of a total of 126 patients who received the first-line treatment with oxaliplatin plus fluoropyrimidine (S-1 or capecitabine or fluorouracil), the second-line treatment with nab-paclitaxel, and the third-line treatment of immune checkpoint inhibitors between September 2019 and December 2021 were analyzed.

Results: A total of 42, 36, and 48 patients received CapeOX, FOLFOX, and SOX as a first-line treatment, respectively. All patients received nab-paclitaxel alone as the second-line treatment. In addition, 31, 56, and 39 patients received nivolumab, sintilimab, and tislelizumab as a third-line treatment, respectively. The median PFS1, median PFS2, and median PFS3 was 6.9 months [95% confidence interval (CI), 6.8−7.4], 5.5 months (95% CI, 5.3−5.7), and 3.5 months (95% CI, 3.3−3.7). The median PFS3 was 3.8 months (95% CI, 3.6−4.2) and 3.5 months (95% CI, 3.3−3.7) in the patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥5 and CPS <5, respectively (P = 0.02). The median OS was 17.4 months (95% CI, 17.2−18.1). The multivariate analysis showed that the two parameters were associated with a significantly longer OS: number of metastatic sites <3 and PD-L1 CPS ≥5.
Conclusion: The patients who received three lines of treatment had a long survival time, and the efficacy of immunotherapy was not affected by the EBV subtypes in advanced GC. The toxicity was managed, and the concept of full management needs to be confirmed in the future.

KEYWORDS
gastric cancer, full management, chemotherapy, immune checkpoint inhibitors, Her-2 negative patients

Introduction

Gastric cancer (GC) is one of the most common cancers, being the third leading cause of cancer death worldwide. Moreover, it is the third leading cause of cancer death in Eastern Asia (1). Surgery is recommended as the mainstay of curative treatment for early-stage patients with GC, but most patients experience relapse after surgery with a high recurrence rate at approximately 40%–80% (2). However, approximately 50% of patients are already locally advanced or have metastasis and lose the surgical opportunity at diagnosis (3). For these patients, systemic chemotherapy is the recommended standard treatment, and the 5-year survival rate is less than 4.5% (4).

First-line chemotherapy prolonged the survival time compared with best supportive care alone in patients with locally advanced or metastatic disease (5, 6). Therefore, the European Society of Medical Oncology and the National Comprehensive Cancer Network recommend the regimen of platinum and fluoropyrimidine as a standard treatment (7). For patients with human epidermal growth factor receptor 2 (Her-2)–negative advanced GC, the median survival time was 12.0 months with treatment of the XELOX or EOX regimen (8). For patients who are Her-2–positive, the TOGA study demonstrated that trastuzumab plus platinum-based chemotherapy prolonged the survival time compared with chemotherapy alone. The median overall survival (OS) was 13.8 months compared with 11.1 months (P = 0.0046) (9).

After failure of the first-line chemotherapy, second-line palliative chemotherapy is recommended as the standard of treatment. Several review and meta-analysis demonstrated the OS advantage of second-line chemotherapy compared with best supportive care (BSC) alone with extended OS by approximately 6.7 months (2, 10, 11). Taxane-based (docetaxel and paclitaxel) and irinotecan are recommended as a standard second-line chemotherapy (12). Ramucirumab alone or combined with paclitaxel also demonstrated the superior efficacy with prolonged OS and recommended as a standard second-line treatment (13, 14). One study shows that weekly paclitaxel used as a second-line treatment revealed a median OS of 5–6 months and overall response rates (ORRs) of 16%–24% in Japan (15). In the phase III WJOG4007 trial, where paclitaxel or irinotecan was used as a second-line treatment for advanced GC, the OS did not show a significant difference between the two groups (16). One study of nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced GC demonstrated that weekly nab-paclitaxel was non-inferior to weekly solvent-based paclitaxel in terms of OS (17).

In one retrospective trial of a single institutional experience, 27% of advanced GC patients received a third-line treatment (18). Many patients have a good general performance after failing the second-line treatment. Evidence shows that third-line or later lines of treatment prolonged the OS in patients with advanced GC. Third-line drugs include irinotecan, taxane, trifluridine/tipiracil (TAS-102), apatinib, and immune checkpoint inhibitors. One phase III randomized trial demonstrated that nivolumab significantly prolonged the OS compared to placebo (19). The median OS of third-line treatment was less 5.0 months. However, there is no report on the efficacy of the first-line to third-line treatments in advanced GC. In this study, we retrospectively evaluated the treatment regimen of oxaliplatin plus oral fluoropyrimidine (S-1 or capecitabine or fluorouracil) in the first line, of nab-paclitaxel in the second line, and immune checkpoint inhibitors in the third line in patients with Her-2–negative advanced GC.

Patients and methods

Patients

In this study, we retrospectively analyzed patients with Her-2–negative metastatic GC. Patients were diagnosed with gastric or gastroesophageal junction adenocarcinoma, who were histologically confirmed at Shandong Cancer Hospital and Institute from September 2019 to December 2021. This study was conducted with the approval of the Shandong Province Tumor Hospital Ethics Committee (2022004008). The eligibility criteria are as follows: older than 18 years, performance status (PS) of 0–2, adequate organ function, no serious clinical complications, no measurable central nervous system
metastasis, and evaluable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) criteria; patients were treated with the first-line therapy of oxaliplatin plus fluoropyrimidine (S-1 or capcitabine or fluorouracil), the second-line therapy of nab-paclitaxel, and the third-line therapy of immune checkpoint inhibitors.

Treatment and evaluation of response

Patients were treated with first-line SOX (oxaliplatin at 130 mg/m² on day 1 plus oral S-1 at 40 mg/m² twice a day, on days 1–14, every 3 weeks), CapeOX (oxaliplatin at 130 mg/m² on day 1 plus capecitabine at 1,000 mg/m² twice a day, on days 1–14, every 3 weeks), or FOLFOX (fluorouracil at 400 mg/m² on day 1 and at 1,200 mg/m² on days 1–2, oxaliplatin at 85 mg/m² on day 1, and leucovorin at 400 mg/m² on day 1, every 2 weeks) for up to 6 months, and after that, patients without evidence of disease progression received maintenance treatment with S-1 or capcitabine or fluorouracil. A second-line treatment with nab-paclitaxel at 100 mg/m² was administered weekly (on days 1, 8, and 15) every 4 weeks and was continued without limitation of maximum treatment cycles until disease progression and occurrence of unacceptable severe toxicity. The third-line of immune checkpoint inhibitors that were a third-line treatment (nivolumab, 3 mg/kg; sintilimab, 200 mg; and tislelizumab 200 mg, intravenously) was administered every 3 weeks alone. A third-line treatment was given until disease progression, occurrence of unacceptable toxicity, and up to a maximum of 2 years. Toxicity evaluations were evaluated by the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 4.0. The dose reductions were decided on the basis of the patient’s general condition and the hematological and nonhematological toxicity. Tumor response was evaluated by computerized tomography images every two or three cycles and was classified by the standard RECIST, version 1.1.

Statistical analysis

Progression-free survival (PFS) was calculated from the first day of each regimen, respectively, to the date of disease progression (PFS1 was calculated from the first day of the first-line treatment regimen to the date of disease progression; PFS2 was calculated from the first day of the second-line treatment regimen to the date of disease progression; and PFS3 was calculated from the first day of the third-line treatment regimen to the date of disease progression). OS was defined as the date of initiation of first-line chemotherapy to the time of death. The Kaplan–Meier method was used to calculate OS and PFS. Descriptive statistics were presented with percentage and medians. Statistical analyses were calculated using SPSS software (version 18.0, SPSS Inc., Chicago, IL, USA), and P-values less than 0.05 were considered significant.

Results

Patient characteristics

In this study, we retrospectively analyzed 352 patients with Her-2–negative metastatic GC, and 126 patients were included in

| Characteristic         | n (%)              |
|------------------------|--------------------|
| Age, years             |                    |
| Median age (range)     | 57 (37–78)        |
| Sex                    |                    |
| Male                   | 74 (58.7%)        |
| Female                 | 52 (41.3%)        |
| Performance status     |                    |
| 0–1                    | 87 (69.0%)        |
| 2                      | 39 (31.0%)        |
| Tumor location         |                    |
| Gastric                | 97 (76.9%)        |
| Gastroesophageal junction |              |
| Metastatic sites       |                    |
| Liver                  | 46 (36.5%)        |
| Peritoneum             | 28 (22.2%)        |
| Lymph node             | 52 (41.3%)        |
| PD-L1                  |                    |
| ≥5                     | 25 (19.8%)        |
| <5                     | 101 (80.2%)       |
| EBV                    |                    |
| Positive               | 19 (15.1%)        |
| Negative               | 107 (84.9%)       |
| First-line chemotherapy|                    |
| CapeOX                 | 42 (33.3%)        |
| FOLFOX                 | 36 (28.6%)        |
| SOX                    | 48 (38.1%)        |
| Time to progressive disease on first-line therapy (PFS 1) | |
| <6 months              | 35 (27.8%)        |
| ≥6 months              | 81 (72.2%)        |
| Second-line chemotherapy|                |
| Nab-paclitaxel         | 126                |
| Time to progressive disease on second therapy (PFS 2) | |
| PFS <5 months          | 49 (38.9%)        |
| PFS ≥5 months          | 77 (61.1%)        |
| Third-line treatment   |                    |
| Nivolumab              | 31 (24.6%)        |
| Sintilimab             | 56 (44.4%)        |
| Tislelizumab           | 39 (31.0%)        |
| Time to progressive disease on third therapy (PFS 3) | |
| PFS <2 months          | 47 (37.3%)        |
| PFS ≥2 months          | 79 (62.7%)        |
this retrospective study; the patient characteristics are presented in Table 1. The median age was 57 years (range, 37–78), and the primary tumor site included the stomach (76.9%) and gastroesophageal junction (23.1%). Eighty patients (69.0%) were presented in the Eastern Cooperative Oncology Group (ECOG) PS of 0–1. The metastasis mainly included the distant lymph nodes (41.3%), liver (36.5%), and peritoneum (22.2%). In addition, 25 patients (19.8%) underwent PD-L1 combined positive score (CPS) ≥5, and 19 patients (15.1%) showed EBV positivity. In these patients, 42 (33.3%), 36 (28.6%), and 48 patients (38.1%) received CapeOX, FOLFOX, and SOX regimens, respectively, as a first-line treatment. All patients received nab-paclitaxel alone as a second-line treatment. In addition, 31 (24.6%), 56 (44.4%), and 39 patients (31.0%) received nivolumab, sintilimab, and tislelizumab, respectively, as a third-line treatment.

**Treatment administration and response**

In the first-line treatment, the ORR and disease control rate (DCR) were 39.7% and 84.1%, respectively. The median PFS1 was 6.9 months (95% CI, 6.8–7.4 months) (Figure 1A). The median PFS1 was 7.5 months (95% CI, 6.4–7.9 months) and 6.8 months (95% CI, 6.2–7.4 months) in the patients with PD-L1 CPS ≥5 and CPS <5, respectively (P = 0.12) (Figure 1B). The median PFS1 was 7.6 months (95% CI, 6.7–8.0 months) and 6.9 months (95% CI, 6.3–7.5 months) among patients who are EBV-positive and EBV-negative, respectively (P = 0.18) (Figure 1C).

In the second-line therapy, all patients received treatment with nab-paclitaxel, and the median PFS2 was 5.5 months (95% CI, 5.3–5.7 months) (Figure 2A). The ORR and DCR were 29.4% and 73.1%, respectively. The median PFS2 was 5.7 months (95% CI, 5.1–6.1 months) and 4.9 months (95% CI, 4.4–5.4 months) in the patients with PD-L1 CPS ≥5 and CPS <5, respectively (P = 0.14) (Figure 2B). The median PFS2 was 5.6 months (95% CI, 5.3–5.9 months) and 5.6 months (95% CI, 5.2–5.8 months) among patients who are EBV-positive and EBV-negative, respectively (P = 0.53) (Figure 2C). For the third-line treatment with nivolumab or sintilimab or tislelizumab, no complete response was observed, and the median PFS3 was 3.5 months (95% CI, 3.4–3.7 months) (Figure 3A). In addition, the ORR and DCR were 11.1% and 53.2%, respectively (Table 2). The median PFS3 was 4.6 months (95% CI, 3.8–4.8 months) and 3.4 months (95% CI, 3.2–3.6 months) in the patients with PD-L1 CPS ≥5 and CPS <5, respectively (P = 0.09) (Figure 3B). In addition, the median PFS3 was 3.8 months (95% CI, 3.3–4.2 months) and 3.5 months (95% CI, 3.3–3.7 months) among patients who are EBV-positive and EBV-negative, respectively (P = 0.02) (Figure 3C). The median OS was 17.4 months (95% CI, 17.2–18.1 months) (Figure 4A), and the median OS was 18.9 months and 17.4 months in the patients with PD-L1 CPS ≥5 and CPS <5, respectively (P = 0.03) (Figure 4B).
**FIGURE 2**
PFS2. (A) Kaplan–Meier plots for PFS2 in the second-line treatment. (B) PFS2 according to PD-L1 (P = 0.36). (C) PFS2 according to EBV (P = 0.46).

**FIGURE 3**
PFS3. (A) Kaplan–Meier plots for PFS3 in the third-line treatment. (B) PFS3 according to PD-L1 (P = 0.02). (C) PFS3 according to EBV (P = 0.09).
Prognostic factors and adverse events

For the prognostic factors, we analyzed some potential characteristics for affecting OS by multivariate analysis. There were two parameters associated with a significantly longer OS: number of metastatic sites ≤3 and PD-L1 CPS ≥5 (Table 3). The state of EBV did not affect the OS. The toxicity mainly included hematological and nonhematological parameters (Table 4). The most common grade 3–4 hematological toxicity was neutropenia (20.6%), anemia (2.4%), and thrombocytopenia (3.9%). Grade 3–4 nonhematological toxicities included nausea (3.9%), diarrhea (4.8%), and mucositis (3.9%), and fatigue (7.9%). There were no treatment-related deaths.

Discussion

For advanced GC, a standard palliative treatment is chemotherapy-based, which improves the quality of life and prolongs survival compared with best supportive care alone. Fluoropyrimidine plus platinum have been demonstrated to have survival benefits in the first-line treatment for advanced GC (20, 21). In advanced GC, Her-2 amplification or overexpression rate was shown to be approximately 7%–34% (20). Therefore, most patients are Her-2-negative, and the first line treatment of metastatic GC was platinum-based and fluoropyrimidine chemotherapy (22).

Cisplatin has been an important compound in the treatment of patients with GC for many years. With nausea, vomiting, and renal toxicity as side effects, oxaliplatin was also investigated (23) and also demonstrated a similar efficacy when compared with cisplatin (24, 25). In our study, CapeOX, SOX, or FOLFOX as a first-line treatment for metastatic GC showed an ORR of 39.7%, a DCR of 84.1%, and the median PFS of 6.9 months. In the study of first-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-esophageal junction, and esophageal adenocarcinoma, the administered chemotherapy...
regimen included capecitabine and oxaliplatin every 3 weeks or leucovorin, fluorouracil, and oxaliplatin every 2 weeks. The median PFS was 6.0 months (5.6–6.9) in the chemotherapy group alone (26), and the PFS was similar to our study. After progression of the first-line treatment, all patients received treatment with nab-paclitaxel. One study of nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced GC demonstrated that the median PFS was 5.3 months (4.0–5.6) in the weekly nab-paclitaxel group (17). In our study, the PFS was 5.5 months (5.3–5.7), which showed to be more prolonged, compared with above study. In the second-line treatment, the PFS that was affected by the first-line treatment is not known. Some randomized studies demonstrated that the second-line chemotherapy prolongs mOS to approximately 1.5 months compared with BSC alone (27–29). Second-line chemotherapy could improve the quality of life and prolong survival; however, the average benefit of mOS is at 6 weeks (16, 27, 28). Patients who have a long PFS and an excellent PS in the first-line chemotherapy receive the most benefit in the second-line treatment (30).

Most patients with progression in the second-line treatment have an opportunity to receive a third line of therapy or further chemotherapy. Some studies have demonstrated the use of chemotherapy in the third-line treatment in recent years (14, 31, 32). Nishimura et al. conducted one study where 52 patients received irinotecan monotherapy as a third-line treatment in advanced GC, and the median PFS was 2.3 months and the median OS was 4.0 months (33). With the development of immunotherapy, the third-line treatment showed the most promising results in advanced GC. Nivolumab, a human anti-programmed cell death 1 antibody, significantly prolonged the median OS and median PFS compared with the best supportive care as a third-line treatment for advanced GC (19). At present, there is no study to confirm the superior efficacy of a third-line treatment with irinotecan monotherapy or immunotherapy. Patients with MSI-high and EBV subtypes treated with immune checkpoint inhibitors have demonstrated a high efficacy (34, 35). In our study, no patients with MSI-high were included, and patients who EBV-positive did not show a superior survival in the treatment with immune checkpoint inhibitors. This could be attributed to fact that EBV causing GC only afflicts a small percentage of patients, and EBV-related carcinogenesis leads to microsatellite instability within this region (36–38). Compared with other studies, the present median OS and PFS of our study were longer, suggesting that patients who received three lines of treatment have a good prognosis. Some studies have shown that the EBV and PD-L1 expression were related to the efficacy of immunotherapy. In contrast, EBV and PD-L1 expression were not related to the efficacy of chemotherapy.

In conclusion, patients who received three lines of treatment may have a long survival time, and the efficacy of immunotherapy was not affected by the EBV subtypes. The toxicity was managed, and no patients died because of toxicity. Our study has some

### TABLE 3 Multivariate analysis for OS.

|                              | HR  | 95% CI     | p    |
|------------------------------|-----|------------|------|
| ECOG PS (0–1 vs. 2)          | 0.63| 0.32–1.08  | 0.31 |
| Age (<65 vs. ≥65 years)      | 1.42| 0.58–2.91  | 0.96 |
| PFS 1 (<6 vs. ≥6 months)     | 0.61| 0.34–1.24  | 0.31 |
| PFS 2 (<5 vs. ≥5 months)     | 0.73| 0.39–1.61  | 0.39 |
| PFS 3 (<2 vs. ≥2 months)     | 1.78| 0.81–3.42  | 0.18 |
| Metastatic sites (<3 vs. ≥3) | 4.87| 2.29–6.64  | 0.01 |
| PD-L1 (CPS <5 vs. ≥5)        | 3.42| 2.43–5.02  | 0.03 |
| EBV (positive vs. negative)  | 1.23| 0.76–3.45  | 0.71 |

HR, hazard ratio.

### TABLE 4 Adverse events.

|                              | All grades | Grade≥3 |
|------------------------------|------------|---------|
| Hematologic                  |            |         |
| Neutropenia                  | 40 (31.7%) | 26 (20.6%) |
| Anemia                       | 23 (18.3%) | 3 (2.4%) |
| Thrombocytopenia             | 28 (22.2%) | 5 (3.9%) |
| Non-hematologic              |            |         |
| Nausea                       | 39 (30.9%) | 5 (3.9%) |
| Vomiting                     | 19 (15.1%) | 4 (3.2%) |
| Diarrhea                     | 14 (11.1%) | 6 (4.8%) |
| Mucositis                    | 15 (11.9%) | 5 (3.9%) |
| Anemia                       | 11 (8.7%)  | 3 (2.4%) |
| Fatigue                      | 18 (14.3%) | 5 (3.9%) |

Frontiers in Oncology
limitations with a retrospective analysis in a single center and a small number of patients who received full management from first-line to third-line treatments. This needs a large population of patients to confirm the efficacy of a complete management in advanced GC.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by Shandong Province Tumor Hospital Ethics Committee (2020-004008). Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

Author contributions

CC and YP performed the experiments, analyzed the data and prepared the manuscript. JX and WZ aided the data analysis and manuscript preparation. JZ contributed data analysis. SS designed and supervised the study, analyzed the data, prepared and revised the manuscript. All authors read and approved the final manuscript.

Funding

This research was supported by the Start-up fund of Shandong Cancer Hospital (2020-PYB11).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6):394-424. doi: 10.3322/caac.21492.
2. Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba R, Li J, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MGS, SSO and TOS. Ann Oncol (2019) 30(1):19e33. doi: 10.1093/annonc/mdy502.
3. Marrelli D, Polom K, Pascale V, Vindigni C, Piagnerelli R, De Franco L, et al. Strong prognostic value of microsatellite instability in intestinal type non-cardia gastric cancer. Ann Surg Oncol (2016) 23(3):943-50. doi: 10.1245/s10434-015-4931-3.
4. Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, et al. Docetaxel plus cisplatin and s-1 versus cisplatin and s-1 in patients with advanced gastric cancer (ECOG1013): An open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol (2019) 4:501–10. doi: 10.1016/S2468-1253(19)30083-4.
5. Wagner AD, Grothe W, Haertert J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol (2006) 24(18):2903e9. doi: 10.1200/JCO.2005.03.8245.
6. Digkia A, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol (2016) 22(8):2403e14. doi: 10.3748/wjg.v22.i8.2403.
7. Ajani JA, D’Amico TA, Alhammna K, Bentrem DJ, Chao J, Das P, et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw (2016) 14(10):1286e312. doi: 10.6004/jnccn.2016.0137.
8. Zhu XD, Huang MZ, Wang YS, Feng WJ, Chen ZY, Ye YF, et al. XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX). Cancer Commun (2012) 42:314–26. doi: 10.1002/cac.21278.
9. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (2010) 376:687–97. doi: 10.1016/S0140-6736(10)61121-X.
10. Liep a A, Mitchell S, Batson S, Gao J, Wang G, Tao K. Systematic review and meta-analysis of recommended second-line therapies for advanced gastric cancer (GC). Eur Cancer Congr 2015 Vienna Austria. ECC (2015). doi: 10.1016/S0959-8049(16)31230-8.
11. Wagner AD, Syn NL, Moehler M, Grothey W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev (2017) 8:CD004064. doi: 10.1002/14651858.CD004064.pub4.
12. Zhu X, Ko YJ, Berry S, Shah K, Lee E, Chan K, et al. A Bayesian network meta-analysis on second-line systemic therapy in advanced gastric cancer. Cancer (2017) 20:646-54. doi: 10.1016/S1049-3237(17)30313-3.
13. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma ( REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (2014) 383:31–9. doi: 10.1016/S0140-6736(13)61719-5.
14. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol (2014) 15:1224–35. doi: 10.1016/S1470-2045(14)70420-6.
15. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onezawa Y. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. *Gastric Cancer* (2006) 9:14–8. doi: 10.1007/s10120-005-0351-6

16. Kodaeda Y, Ito S, Morizaki Y, Fujita K, Koshikawa K, Kanyama Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCG0302 study). *Anticancer Res* (2007) 27:2667–71.

17. Shitara K, Takahashi A, Fujitani K, Koea K, Hara H, Nakayama N, et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. *Lancet Gastroenterol Hepatol* (2017) 2(4), 277–87. doi: 10.1016/S2468-1253(16)30219-9

18. Koo DH, Ryu M-H, Ryou B-Y, Seo J, Lee M-Y, Chang H-M, et al. Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution. *Gastric Cancer* (2015) 18(2):346–53. doi: 10.1007/s10120-014-0385-8

19. Kang YK, Boku N, Sato T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATT RAC TION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* (2017) 390:2461–71. doi: 10.1016/S0140-6736(17)31827-5

20. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* (2010) 376:687–97. doi: 10.1016/S0140-6736(10)61121-X

21. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus capecitabine versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. *Lancet Oncol* (2008) 9:215–21. doi: 10.1016/S1470-2045(08)70035-4

22. Petrelli R, Roviello G, Zanotti L, Roviello F, Polom K, Bottini A, et al. Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric cancer: A systematic review and meta-analysis. *Crit Rev Oncol Hematol* (2016) 102:82–8. doi: 10.1016/j.critrevonc.2016.04.001

23. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. *Cochrane Database Syst Rev* (2010) 3): CD004064. doi: 10.1002/14651858.CD004064.pub3

24. Al-Batran SE, Hartmann JT, Probst S, Schmaling H, Hollerbach S, Hothenz R, et al. Phase III trial in metastatic gastrointestinal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft interdisziplinäre onkologie. J Clin Oncol (2008) 26:1435–42. doi: 10.1200/JCO.2007.13.9378

25. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophageal cancer. *N Engl J Med* (2008) 358:36–46. doi: 10.1056/NEJMoa073149

26. Janiogn Y, Shitara K, Moehler M, Garrido M, Salmon P, Shen L, et al First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastroesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. *Lancet* (2021). 398(10294):27–40. doi: 10.1016/S0140-6736(21)00797-2

27. Thuss-Patience PC, Kretzschmar A, Bichsel D, Deitl T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the arbeitsgemeinschaft interdisziplinäre onkologie (AIO). *Eur J Cancer* (2011) 47:2306–14. doi: 10.1016/j.ejca.2011.06.002

28. Kang JH, Lee SI, Lim do H, Park K-W, Oh SY, Kwon H-C, et al. Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. *J Clin Oncol* (2012) 30:1513–9. doi: 10.1200/JCO.2011.39.4585

29. Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadley J, et al. Docetaxel versus active symptom control for refractory esophageopagastic adenocarcinoma (COUGAR-02): An open-label, phase 3 randomised controlled trial. *Lancet Oncol* (2014) 15:78–86. doi: 10.1016/S1470-2045(13)70549-7

30. Janitzow T, Thuss-Patience P, Marshall A, Kang JH, Connell C, Cook N, et al. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: A meta-analysis of patient-level data. *Br J Cancer* (2016) 114:381–87. doi: 10.1038/bjc.2015.452

31. Davidson M, Caferger C, Goode EF, Kouvelakis K, Hughes D, Reguera P, et al. Survival in advanced oesophageopagastic adenocarcinoma improves with the use of multiple lines of therapy: results from an analysis of more than 500 patients. *Clin Colorectal Cancer* (2017) 18:223–30. doi: 10.1016/j.clcc.2018.05.014

32. Hess LM, Michael D, Mytelka DS, Beyer J, Liepa AM, Nicol S, et al. Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the united states: a retrospective analysis of electronic medical record (EMR) and administrative claims data. *Gastric Cancer* (2016) 19:607–15. doi: 10.1007/s10120-015-0486-z

33. Nishiura T, Iwasa S, Nagashima K, Okita N, Takashima A, Henma Y, et al. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. *Gastric Cancer* (2017) 20 (4), 655–662. doi: 10.1007/s10120-016-0670-9

34. Kim ST, Cristescu R, Bass AJ, Kim K-M, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. *Nat Med* (2018) 24(9):1449–58. doi: 10.1038/nmat.5188-01101-z

35. Le DT, Kavan P, Kim TW, Geva R, Jager D, Hara H, et al. KEYNOTE-164 pembrolizumab for patients with advanced microsatellite instability high (MSI-h) colorectal cancer. *J Clin Oncol* (2018) 36(Suppl 15):3514. doi: 10.1200/JCO.2018.36.15_suppl.3514

36. Lee HS, Chang MS, Yang HK, Lee BL, Kim WH. Epstein-Barr Virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma. *Clin Cancer Res* (2014) 10:1698–705. doi: 10.1158/1078-0432.CCR-13-2123

37. Fuchs CS, Doi T, Jang RW, Muro K, Sato T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical keynote-059 trial. *JAMA Oncol* (2018) 4(5):e180013. doi: 10.1001/jamaoncol.2018.0013

38. Hironaka S, Ueda S, Yasui H, Nishina T, Takashima A, Henma Y, et al. Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. *J Clin Oncol* (2012) 30:1513–9. doi: 10.1200/JCO.2011.39.4585